SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation

YH Chan, TF Chao, SW Chen, HF Lee… - The Journal of …, 2024 - academic.oup.com
Context The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with
substantial risks of adverse cardiovascular events. Objective The relevant outcomes …
相关文章

SGLT2 inhibitors vs. GLP-1 receptor agonists and clinical outcomes in patients with diabetes with/without atrial fibrillation

YH Chan, TF Chao, SW Chen, HF Lee… - The Journal of … - pubmed.ncbi.nlm.nih.gov
Context The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with
substantial risks of adverse cardiovascular events. Objective The relevant outcomes …

SGLT2 inhibitors vs. GLP-1 receptor agonists and clinical outcomes in patients with diabetes with/without atrial fibrillation.

YH Chan, TF Chao, SW Chen, HF Lee… - The Journal of …, 2024 - europepmc.org
The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with substantial
risks of adverse cardiovascular events. The relevant outcomes associated with the use of …

SGLT2 inhibitors vs. GLP-1 receptor agonists and clinical outcomes in patients with diabetes with/without atrial fibrillation

YH Chan, TF Chao, SW Chen, HF Lee, PR Li… - The Journal of clinical …, 2024 - vbn.aau.dk
CONTEXT: The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with
substantial risks of adverse cardiovascular events. OBJECTIVE: The relevant outcomes …

SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation

YH Chan, TF Chao, SW Chen, HF Lee, PR Li… - The Journal of Clinical … - academic.oup.com
Objective The relevant outcomes associated with the use of a sodium–glucose cotransporter-
2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) among …